In particular, while VEGFR inhibition alone can still allow tumour spread, due to the activation of the parallel hypoxia-induced MET signalling, this TKI can concurrently block both pathways, resulting in enhanced disease control (Fig. 1) [1]. The gene discussed is KDR; the disease is neoplasm.